Publications by authors named "Deborah Hagan"

Claim this Profile
I
Identification of small-molecule protein-protein interaction inhibitors for NKG2D.
Aaron A Thompson, Michael B Harbut, Pei-Pei Kung, Nathan K Karpowich, Jeffrey D Branson, Deborah Hagan

Proc Natl Acad Sci U S A· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
Mark Tirmenstein, Thomas E Dorr, Evan B Janovitz, Deborah Hagan, Lynn M Abell

Int J Toxicol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan

Diabetes Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
Bruce A Ellsworth, Wei Meng, Manorama Patel, Ravindar N Girotra, Gang Wu, Deborah L Hagan

Bioorg Med Chem Lett· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Songping Han, Deborah L Hagan, Joseph R Taylor, Li Xin, Wei Meng

Diabetes· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Wei Meng, Bruce A Ellsworth, Alexandra A Nirschl, Peggy J McCann, Manorama Patel, Deborah L Hagan

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis